{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:27:02Z","timestamp":1786768022719,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.msard.2021.103168","type":"journal-article","created":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T01:22:40Z","timestamp":1627176160000},"page":"103168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Therapeutic plasma exchange in MS refractory relapses: Long-term outcome"],"prefix":"10.1016","volume":"55","author":[{"given":"M.","family":"Marrodan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Crema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rubstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Correale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Ysrraelit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.msard.2021.103168_bib0001","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/jnnp.56.11.1219","article-title":"Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose","volume":"56","author":"Alam","year":"1993","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9056","key":"10.1016\/j.msard.2021.103168_bib0002","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0140-6736(96)06453-7","article-title":"Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis","volume":"349","author":"Barnes","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.msard.2021.103168_bib0003","first-page":"799","article-title":"Acute multiple sclerosis relapse","volume":"22","author":"Berkovich","year":"2016","journal-title":"Continuum. (Minneap. Minn.)"},{"key":"10.1016\/j.msard.2021.103168_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420975642","article-title":"Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study","volume":"14","author":"Blechinger","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"8","key":"10.1016\/j.msard.2021.103168_bib0005","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/brain\/awz156","article-title":"Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis","volume":"142","author":"Brownlee","year":"2019","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2021.103168_bib0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/1352458511417479","article-title":"Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis","volume":"18","author":"Cossburn","year":"2012","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2021.103168_bib0007","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/1744-9987.12176","article-title":"Therapeutic plasma exchange in glucocorticosteroid-unresponsive patients with Clinically Isolated Syndrome","volume":"18","author":"Ehler","year":"2014","journal-title":"Ther. Apher. Dial."},{"issue":"8","key":"10.1016\/j.msard.2021.103168_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134583","article-title":"Response to therapeutic plasma exchange as a rescue treatment in clinically isolated syndromes and acute worsening of multiple sclerosis: a retrospective analysis of 90 patients","volume":"10","author":"Ehler","year":"2015","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.msard.2021.103168_bib0009","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1212\/01.wnl.0000260970.63493.c8","article-title":"Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide","volume":"68","author":"Greenberg","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2021.103168_bib0010","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1744-9987.2009.00794.x","article-title":"Treatment of steroid unresponsive relapse with plasma exchange in aggressive multiple sclerosis","volume":"14","author":"Habek","year":"2010","journal-title":"Ther. Apher. Dial."},{"issue":"3","key":"10.1016\/j.msard.2021.103168_bib0011","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2021.103168_bib0012","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJM198301273080401","article-title":"Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH","volume":"308","author":"Hauser","year":"1983","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.msard.2021.103168_bib0013","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neuro."},{"issue":"1","key":"10.1016\/j.msard.2021.103168_bib0014","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","article-title":"Plasma exchange for severe attacks of CNS demyelination: predictors of response","volume":"58","author":"Keegan","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103168_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2019.04.017","article-title":"Worsening of disability caused by relapses in multiple sclerosis: A different approach","volume":"32","author":"Koch-Henriksen","year":"2019","journal-title":"Mult. Scler Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2021.103168_bib0016","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2021.103168_bib0017","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/1352458507084650","article-title":"Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study","volume":"14","author":"Leone","year":"2008","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.msard.2021.103168_bib0018","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.0b013e3181b879be","article-title":"Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months","volume":"73","author":"Llufriu","year":"2009","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2021.103168_bib0019","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1212\/01.WNL.0000096175.39831.21","article-title":"Effect of relapses on development of residual deficit in multiple sclerosis","volume":"61","author":"Lublin","year":"2003","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2021.103168_bib0020","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) advisory committee on clinical trials of new agents in multiple sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2021.103168_bib0021","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archneurol.2011.34","article-title":"Beneficial plasma exchange response in central nervous system inflammatory demyelination","volume":"68","author":"Maga\u00f1a","year":"2011","journal-title":"Arch. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2021.103168_bib0022","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1212\/01.wnl.0000342458.39625.91","article-title":"Demyelinating events in early multiple sclerosis have inherent severity and recovery","volume":"17","author":"Mowry","year":"2009","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2021.103168_bib0023","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1212\/WNL.56.11.1514","article-title":"A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis","volume":"56","author":"Noseworthy","year":"2001","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2021.103168_bib0024","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1212\/WNL.0000000000001856","article-title":"Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis","volume":"85","author":"Novotna","year":"2015","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2021.103168_bib0025","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1212\/01.WNL.0000128136.79044.D6","article-title":"Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects","volume":"62","author":"O'Connor","year":"2004","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2021.103168_bib0026","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1007\/s10072-020-04382-w","article-title":"Plasma exchange in acute attacks of demyelinating diseases of the central nervous system: clinical outcomes and predictors of response","volume":"41","author":"Palacios-Mendoza","year":"2020","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2021.103168_bib0027","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/jcm9010035","article-title":"Comparing plasma exchange to escalated methyl prednisolone in refractory multiple sclerosis relapses","volume":"9","author":"Pfeuffer","year":"2019","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.msard.2021.103168_bib0028","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2021.103168_bib0029","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1161\/STROKEAHA.109.557256","article-title":"Reliability of the modified rankin scale: a systematic review","volume":"40","author":"Quinn","year":"2009","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.msard.2021.103168_bib0030","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/1352458513508835","article-title":"A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS","volume":"20","author":"Ramo-Tello","year":"2014","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2021.103168_bib0031","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.msard.2021.103168_bib0032","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3390\/jcm8101623","article-title":"Therapeutic apheresis in acute relapsing multiple sclerosis: current evidence and unmet needs-a systematic review","volume":"8","author":"Rolfes","year":"2019","journal-title":"J. Clin. Med."},{"issue":"Pt 1","key":"10.1016\/j.msard.2021.103168_bib0033","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/brain\/116.1.117","article-title":"Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up","volume":"116","author":"Runmarker","year":"1993","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.msard.2021.103168_bib0034","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s00115-005-2019-1","article-title":"Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients","volume":"77","author":"Schilling","year":"2006","journal-title":"Nervenarzt"},{"issue":"9","key":"10.1016\/j.msard.2021.103168_bib0035","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1586\/ern.09.81","article-title":"Plasmapheresis for neurological disorders","volume":"9","author":"Schr\u00f6der","year":"2009","journal-title":"Expert. Rev. Neurother."},{"issue":"12","key":"10.1016\/j.msard.2021.103168_bib0036","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1468-1331.2005.01352.x","article-title":"EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses","volume":"12","author":"Sellebjerg","year":"2005","journal-title":"Eur. J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2021.103168_bib0037","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1212\/01.WNL.0000145798.61383.39","article-title":"IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS","volume":"63","author":"Sorensen","year":"2004","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2021.103168_bib0038","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12883-017-0927-x","article-title":"Outcome of MS relapses in the era of disease-modifying therapy","volume":"17","author":"Stoppe","year":"2017","journal-title":"BMC Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.103168_bib0039","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.103168_bib0040","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000224630","article-title":"Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis","volume":"28","author":"Trebst","year":"2009","journal-title":"Blood. Purif."},{"issue":"1","key":"10.1016\/j.msard.2021.103168_bib0041","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1191\/1352458504ms978sr","article-title":"A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS","volume":"10","author":"Visser","year":"2004","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2021.103168_bib0042","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1098-1101(1999)14:3<144::AID-JCA7>3.0.CO;2-R","article-title":"Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system","volume":"14","author":"Weinshenker","year":"1999","journal-title":"J. Clin. Apher."},{"issue":"6","key":"10.1016\/j.msard.2021.103168_bib0043","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821004351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821004351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T03:37:14Z","timestamp":1786765034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821004351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":43,"alternative-id":["S2211034821004351"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103168","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic plasma exchange in MS refractory relapses: Long-term outcome","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103168"}}